The C6orf47 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the C6orf47 gene. This product introduces targeted gene disruption across a bulk population of HAP1 cells, generating a heterogeneous knockout model that avoids the clonal artifacts often associated with single-cell-derived lines. By ablating C6orf47 function, researchers can systematically investigate the biological roles of this poorly annotated gene in a streamlined experimental system.
The host HAP1 cell line is a near-haploid human cell model derived from the KBM-7 chronic myeloid leukemia line. HAP1 cells harbor the Philadelphia chromosome, resulting in expression of the BCR-ABL1 fusion oncogene, a hallmark of CML pathogenesis. Their near-haploid karyotype??with only one copy of most chromosomes??greatly simplifies genetic manipulation, as a single CRISPR targeting event can produce a functional knockout, minimizing the complications of diploid gene compensation. This characteristic, combined with robust growth and well-characterized hematopoietic properties, makes HAP1 a preferred chassis for genetic screening and functional genomics.
C6orf47 is a gene encoding an uncharacterized protein with no firmly established molecular function. Limited evidence from computational predictions and high-throughput studies suggests potential involvement in cellular signaling or immune-related processes, but definitive upstream regulators, downstream effectors, and interaction partners remain unidentified. Because its biological role is largely undefined, a knockout model in a tractable system like HAP1 provides a critical tool for probing its mechanistic contributions to cellular processes such as proliferation, apoptosis, and stress responses.
In the context of HAP1 cells, disruption of C6orf47 allows researchers to explore its function within a hematopoietic and leukemia-relevant background. The BCR-ABL1-driven signaling environment in HAP1 provides a unique opportunity to assess whether C6orf47 participates in or modifies oncogenic pathways. The polyclonal nature of this product preserves population-level heterogeneity, which can reveal phenotypic variability and buffer against off-target effects, making it well-suited for pooled screening and comparative transcriptomic or drug-response studies.
This C6orf47 knockout model supports a wide range of research applications. Following confirmation of target disruption via Sanger sequencing or Western blotting, cells can be employed in proliferation assays to evaluate growth phenotypes, RNA sequencing for transcriptomic profiling, drug sensitivity testing to identify synthetic lethal interactions, and apoptosis or cell cycle analyses to characterize functional outcomes. The polyclonal format is particularly advantageous for genetic interaction screens and for studying gene function under conditions that mimic the genetic diversity of uncloned populations. For further information, please contact Ascent Research.
